ScreenerHero

RGNXREGENXBIO Inc.

NAS · US · Healthcare · Biotechnology · regenxbio.com
10.72USD-10.82%Mkt Cap: 707.66M $P/E: —

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Techn…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap707.66M $
Enterprise Value875.05M $
Revenue (TTM)174.48M $
Gross Profit150.14M $
Net Income (TTM)-193.88M $
Revenue/Share3.344 USD
Last Price10.72 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees371
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS75901B1070
Valuation
P/E (Trailing)—
P/E (Forward)-4.78
PEG—
EV/EBITDA-5.88
EV/Revenue5.02
P/S4.18
P/B8.35
EPS (TTM)-3.48
EPS (Forward)-2.31
52W Range
5.45549% of range16.19
52W High16.19 USD
52W Low5.455 USD
Profitability
Gross Margin88.09%
Oper. Margin27.09%
EBITDA Margin-85.27%
Profit Margin-113.75%
ROE-188.72%
ROA-42.80%
Growth
Revenue Growth405.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-123.96M $
CapEx (TTM)2.41M $
FCF Margin-105.61%
FCF Yield-26.04%
Net Debt144.94M $
Net Debt/EBITDA-0.97
Balance Sheet
Debt/Equity0.72
Current Ratio2.86
Quick Ratio2.70
Book Value/Sh1.325 USD
Cash/Share1.598 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)24.55 USD
Upside (mean)+129.0%
Target Range10.00 USD – 50.00 USD
$10.00+129.0% to mean$50.00
# Analysts11
Ownership
Shares Out.66.01M
Float57.34M
Insiders6.27%
Institutions65.53%
Short Interest
Short Ratio3.2d
Short % Float11.54%
Short % Out.10.90%
Shares Short7.19M
Short (prev mo.)10.46M
Technical
SMA 5010.66 (+0.6%)
SMA 20010.44 (+2.6%)
Beta0.94
S&P 52W Chg18.16%
Avg Vol (30d)1.55M
Avg Vol (10d)949.31K
Technical Indicators
RSI (14)50.2
MACD0.1781
MACD Signal0.0993
MACD Hist.+0.0788
BB Upper11.74 USD
BB Middle10.45 USD
BB Lower9.155 USD
BB Width24.75%
ATR (14)0.8422 USD
Vol Ratio (20d)0.89x